Skip to main content
Top
Published in: Diabetologia 8/2017

Open Access 01-08-2017 | Article

The human serum protein C4b-binding protein inhibits pancreatic IAPP-induced inflammasome activation

Authors: Klaudia Kulak, Gunilla T. Westermark, Nikolina Papac-Milicevic, Erik Renström, Anna M. Blom, Ben C. King

Published in: Diabetologia | Issue 8/2017

Login to get access

Abstract

Aims/hypothesis

Inflammasome activation and subsequent IL-1β production is a driver of islet pathology in type 2 diabetes. Oligomers, but not mature amyloid fibrils, of human islet amyloid polypeptide (IAPP), which is co-secreted with insulin, trigger NOD-like receptor pyrin domain containing-3 (NLRP3) inflammasome activation. C4b-binding protein (C4BP), present in serum, binds to IAPP and affects transition of IAPP monomers and oligomers to amyloid fibrils. We therefore hypothesised that C4BP inhibits IAPP-mediated inflammasome activation and IL-1β production.

Methods

Macrophages were exposed to IAPP in the presence or absence of plasma-purified human C4BP, and inflammasome activation was assessed by IL-1β secretion as detected by ELISA and reporter cell lines. IAPP fibrillation was assessed by thioflavin T assay. Uptake of IAPP–C4BP complexes and their effects on phagolysosomal stability were assessed by flow cytometry and confocal microscopy. The effect of C4BP regulation of IAPP-mediated inflammasome activation on beta cell function was assessed using a clonal rat beta cell line. Immunohistochemistry was used to examine the association of IAPP amyloid deposits and macrophage infiltration in isolated human and mouse pancreatic islets, and expression of C4BP from isolated human pancreatic islets was assessed by quantitative PCR, immunohistochemistry and western blot.

Results

C4BP significantly inhibited IAPP-mediated IL-1β secretion from primed macrophages at physiological concentrations in a dose-dependent manner. C4BP bound to and was internalised together with IAPP. C4BP did not affect IAPP uptake into phagolysosomal compartments, although it did inhibit its formation into amyloid fibrils. The loss of macrophage phagolysosomal integrity induced by IAPP incubation was inhibited by co-incubation with C4BP. Supernatant fractions from macrophages activated with IAPP inhibited both insulin secretion and viability of clonal beta cells in an IL-1β-dependent manner but the presence of C4BP during macrophage IAPP incubation rescued beta cell function and viability. In human and mouse islets, the presence of amyloid deposits correlated with higher numbers of infiltrating macrophages. Isolated human islets expressed and secreted C4BP, which increased with addition of IL-1β.

Conclusions/interpretation

IAPP deposition is associated with inflammatory cell infiltrates in pancreatic islets. C4BP blocks IAPP-induced inflammasome activation by preventing the loss of macrophage phagolysosomal integrity required for NLRP3 activation. The consequence of this is the preservation of beta cell function and viability. C4BP is secreted directly from human pancreatic islets and this increases in response to inflammatory cytokines. We therefore propose that C4BP acts as an extracellular chaperone protein that limits the proinflammatory effects of IAPP.
Appendix
Available only for authorised users
Literature
1.
go back to reference Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107CrossRefPubMed Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107CrossRefPubMed
2.
go back to reference Ehses JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 106:13998–14003CrossRefPubMedPubMedCentral Ehses JA, Lacraz G, Giroix MH et al (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 106:13998–14003CrossRefPubMedPubMedCentral
3.
go back to reference Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668CrossRefPubMedPubMedCentral Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663–1668CrossRefPubMedPubMedCentral
4.
go back to reference Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526CrossRefPubMed Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526CrossRefPubMed
5.
go back to reference Kahn SE, DA DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634–638CrossRefPubMed Kahn SE, DA DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634–638CrossRefPubMed
6.
go back to reference Masters SL, Dunne A, Subramanian SL et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11:897–904CrossRefPubMedPubMedCentral Masters SL, Dunne A, Subramanian SL et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11:897–904CrossRefPubMedPubMedCentral
7.
go back to reference Jurgens CA, Toukatly MN, Fligner CL et al (2011) β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178:2632–2640CrossRefPubMedPubMedCentral Jurgens CA, Toukatly MN, Fligner CL et al (2011) β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178:2632–2640CrossRefPubMedPubMedCentral
8.
go back to reference Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498CrossRefPubMed Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491–498CrossRefPubMed
9.
go back to reference Sparr E, Engel MF, Sakharov DV et al (2004) Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett 577:117–120CrossRefPubMed Sparr E, Engel MF, Sakharov DV et al (2004) Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett 577:117–120CrossRefPubMed
10.
go back to reference Sheedy FJ, Grebe A, Rayner KJ et al (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14:812–820CrossRefPubMedPubMedCentral Sheedy FJ, Grebe A, Rayner KJ et al (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14:812–820CrossRefPubMedPubMedCentral
11.
go back to reference Sjolander J, Westermark GT, Renstrom E, Blom AM (2012) Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation. J Biol Chem 287:10824–10833CrossRefPubMedPubMedCentral Sjolander J, Westermark GT, Renstrom E, Blom AM (2012) Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation. J Biol Chem 287:10824–10833CrossRefPubMedPubMedCentral
12.
13.
go back to reference Masters SL, LA ON (2011) Disease-associated amyloid and misfolded protein aggregates activate he inflammasome. Trends Mol Med 17:276–282CrossRefPubMed Masters SL, LA ON (2011) Disease-associated amyloid and misfolded protein aggregates activate he inflammasome. Trends Mol Med 17:276–282CrossRefPubMed
14.
go back to reference Mohlin FC, Blom AM (2014) Purification and functional characterization of C4b-binding protein (C4BP). Methods Mol Biol 1100:169–176CrossRefPubMed Mohlin FC, Blom AM (2014) Purification and functional characterization of C4b-binding protein (C4BP). Methods Mol Biol 1100:169–176CrossRefPubMed
15.
go back to reference Blom AM, Kask L, Dahlback B (2001) Structural requirements for the complement regulatory activities of C4BP. J Biol Chem 29:27136–27144CrossRef Blom AM, Kask L, Dahlback B (2001) Structural requirements for the complement regulatory activities of C4BP. J Biol Chem 29:27136–27144CrossRef
16.
go back to reference Westwell-Roper C, Dunne A, Kim ML, Verchere CB, Masters SL (2013) Activating the NLRP3 inflammasome using the amyloidogenic peptide IAPP. Methods Mol Biol 1040:9–18CrossRefPubMed Westwell-Roper C, Dunne A, Kim ML, Verchere CB, Masters SL (2013) Activating the NLRP3 inflammasome using the amyloidogenic peptide IAPP. Methods Mol Biol 1040:9–18CrossRefPubMed
17.
go back to reference Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424–430CrossRefPubMed Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49:424–430CrossRefPubMed
18.
go back to reference Hardig Y, Hillarp A, Dahlback B (1997) The amino-terminal module of the C4b-binding protein alpha-chain is crucial for C4b binding and factor I-cofactor function. Biochem J 323:469–475CrossRefPubMedPubMedCentral Hardig Y, Hillarp A, Dahlback B (1997) The amino-terminal module of the C4b-binding protein alpha-chain is crucial for C4b binding and factor I-cofactor function. Biochem J 323:469–475CrossRefPubMedPubMedCentral
19.
go back to reference Hornung V, Bauernfeind F, Halle A et al (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847–856CrossRefPubMedPubMedCentral Hornung V, Bauernfeind F, Halle A et al (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847–856CrossRefPubMedPubMedCentral
20.
go back to reference Li K, Sacks SH, Zhou W (2007) The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol Immunol 44:3866–3874CrossRefPubMed Li K, Sacks SH, Zhou W (2007) The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies. Mol Immunol 44:3866–3874CrossRefPubMed
21.
go back to reference Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036–5040CrossRefPubMedPubMedCentral Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036–5040CrossRefPubMedPubMedCentral
22.
go back to reference Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC (2004) Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 53:1509–1516CrossRefPubMed Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC (2004) Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 53:1509–1516CrossRefPubMed
24.
go back to reference Sjoberg AP, Trouw LA, Blom AM (2009) Complement activation and inhibition: a delicate balance. Trends Immunol 30:83–90CrossRefPubMed Sjoberg AP, Trouw LA, Blom AM (2009) Complement activation and inhibition: a delicate balance. Trends Immunol 30:83–90CrossRefPubMed
25.
go back to reference Last NB, Rhoades E, Miranker AD (2011) Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity. Proc Natl Acad Sci U S A 108:9460–9465CrossRefPubMedPubMedCentral Last NB, Rhoades E, Miranker AD (2011) Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity. Proc Natl Acad Sci U S A 108:9460–9465CrossRefPubMedPubMedCentral
26.
go back to reference Lacraz G, Giroix MH, Kassis N et al (2009) Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS One 4:e6963CrossRefPubMedPubMedCentral Lacraz G, Giroix MH, Kassis N et al (2009) Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS One 4:e6963CrossRefPubMedPubMedCentral
27.
go back to reference Boni-Schnetzler M, Boller S, Debray S et al (2009) Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150:5218–5229CrossRefPubMed Boni-Schnetzler M, Boller S, Debray S et al (2009) Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150:5218–5229CrossRefPubMed
28.
go back to reference Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced β cell production of interleukin-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–869CrossRefPubMedPubMedCentral Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced β cell production of interleukin-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–869CrossRefPubMedPubMedCentral
29.
go back to reference Papaccio G, Graziano A, DʼAquino R, Valiante S, Naro F (2005) A biphasic role of nuclear transcription factor (NF)-κB in the islet β-cell apoptosis induced by interleukin (IL)-1β. J Cell Physiol 204:124–130CrossRefPubMed Papaccio G, Graziano A, DʼAquino R, Valiante S, Naro F (2005) A biphasic role of nuclear transcription factor (NF)-κB in the islet β-cell apoptosis induced by interleukin (IL)-1β. J Cell Physiol 204:124–130CrossRefPubMed
30.
go back to reference Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA (2009) Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 24:325–331CrossRef Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA (2009) Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 24:325–331CrossRef
31.
go back to reference Westwell-Roper C, Dai DL, Soukhatcheva G et al (2011) IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 187:2755–2765CrossRefPubMed Westwell-Roper C, Dai DL, Soukhatcheva G et al (2011) IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 187:2755–2765CrossRefPubMed
32.
go back to reference Mandrup-Poulson T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005–1029CrossRef Mandrup-Poulson T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005–1029CrossRef
33.
go back to reference Krus U, King BC, Nagaraj V et al (2014) The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events. Cell Metab 19:883–890CrossRefPubMed Krus U, King BC, Nagaraj V et al (2014) The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events. Cell Metab 19:883–890CrossRefPubMed
34.
35.
go back to reference Takahashi H, Tatewaki W, Wada K, Shibata A (1989) Plasma protein S in disseminated intravascular coagulation, liver disease, collagen disease, diabetes mellitus, and under oral anticoagulant therapy. Clin Chim Acta 182:195–208CrossRefPubMed Takahashi H, Tatewaki W, Wada K, Shibata A (1989) Plasma protein S in disseminated intravascular coagulation, liver disease, collagen disease, diabetes mellitus, and under oral anticoagulant therapy. Clin Chim Acta 182:195–208CrossRefPubMed
36.
go back to reference Nybo M, Nielsen EH, Svehag SE (1999) Complement activation by the amyloid proteins Aβ peptide and β2-microglobulin. Amyloid 6:265–272CrossRefPubMed Nybo M, Nielsen EH, Svehag SE (1999) Complement activation by the amyloid proteins Aβ peptide and β2-microglobulin. Amyloid 6:265–272CrossRefPubMed
38.
go back to reference King BC, Nowakowska J, Karsten CM, Kohl J, Renstrom E, Blom AM (2012) Truncated and full-length thioredoxin-1 have opposing activating and inhibitory properties for human complement with relevance to endothelial surfaces. J Immunol 188:4103–4112CrossRefPubMed King BC, Nowakowska J, Karsten CM, Kohl J, Renstrom E, Blom AM (2012) Truncated and full-length thioredoxin-1 have opposing activating and inhibitory properties for human complement with relevance to endothelial surfaces. J Immunol 188:4103–4112CrossRefPubMed
39.
go back to reference Gil-Bea F, Akterin S, Persson T et al (2012) Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimerʼs disease brain. EMBO Mol Med 4:1097–1111CrossRefPubMedPubMedCentral Gil-Bea F, Akterin S, Persson T et al (2012) Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimerʼs disease brain. EMBO Mol Med 4:1097–1111CrossRefPubMedPubMedCentral
40.
go back to reference Trouw LA, Nielsen HM, Minthon L et al (2008) C4b-binding protein in Alzheimerʼs disease: binding to Aβ1-42 and to dead cells. Mol Immunol 45:3649–3660CrossRefPubMed Trouw LA, Nielsen HM, Minthon L et al (2008) C4b-binding protein in Alzheimerʼs disease: binding to Aβ1-42 and to dead cells. Mol Immunol 45:3649–3660CrossRefPubMed
41.
go back to reference Sjoberg AP, Nystrom S, Hammarstrom P, Blom AM (2008) Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly. Mol Immunol 45:3213–3221CrossRefPubMed Sjoberg AP, Nystrom S, Hammarstrom P, Blom AM (2008) Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly. Mol Immunol 45:3213–3221CrossRefPubMed
Metadata
Title
The human serum protein C4b-binding protein inhibits pancreatic IAPP-induced inflammasome activation
Authors
Klaudia Kulak
Gunilla T. Westermark
Nikolina Papac-Milicevic
Erik Renström
Anna M. Blom
Ben C. King
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4286-3

Other articles of this Issue 8/2017

Diabetologia 8/2017 Go to the issue